استمتع بـUnlimited مع Magzter GOLD

استمتع بـUnlimited مع Magzter GOLD

احصل على وصول غير محدود إلى أكثر من 9000 مجلة وصحيفة وقصة مميزة مقابل

$149.99
 
$74.99/سنة

يحاول ذهب - حر

APAC'S ALLIANCE-DRIVEN BIOTECH BOOM

BioSpectrum Asia June 2025

|

BioSpectrum Asia

Partnerships are a cornerstone of the biotech innovation process. COVID-19 acted as a catalyst, accelerating collaboration across the sector and prompting partnerships between established players for the first time.

- Ayesha Siddiqui

APAC'S ALLIANCE-DRIVEN BIOTECH BOOM

Since then, biotech alliances have become more diverse, frequent, and strategically important, especially in the Asia-Pacific (APAC) region. Biotech partnerships of APAC differ in a variety of ways from most global collaborations, primarily due to the unique geopolitical and socio-economic landscape of the region. The region has innovation hubs like Japan and South Korea as well as large, high-growth markets such as China and India. As China rapidly scales its biopharma capabilities, it is becoming both a key market and an innovator. This transformation has redefined regional deal-making, shifting the focus from technology transfer to co-development, shared commercialisation, and strategic alignment. APAC biotech deals are no longer early-stage R&D plays, they are beginning to span the full lifecycle, from bench to bedside, including commercialisation milestones. Let's explore further the APAC's wave of regional biotech partnerships during the first five months of this calendar year ie. from January to May 2025.

In the first half of 2025, up to May 20, the APAC biotech industry has seen a surge in regional partnerships. A total of 24 partnerships have been recorded so far, spanning areas such as antibody-drug conjugates (ADCs), digital health, contract development and manufacturing (CDMO), AI-driven diagnostics, and gene therapy.

China, of course, stands out as the region’s most prolific participant in these partnerships. Chinese firms are involved in over half of the collaborations recorded during this period, particularly in areas like ADCs, CDMO services, AI-powered diagnostics, and imaging systems. Companies such as WuXi XDC, Minghui Pharmaceutical, Belief BioMed, and United Imaging exemplify how Chinese biotech and medtech companies are forming both domestic and cross-border alliances to consolidate their leadership in innovation and manufacturing.

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Listen

Translate

Share

-
+

Change font size